Ligand id: 8713

Name: brolucizumab

No information available.
Summary of Clinical Use
Outcomes from Phase 3 studies that compared brolucizumab therapy to treatment with the VEGF trap agent aflibercept, were published in April 2019 [3]. Brolucizumab was found to be non-inferior to the comparator agent and overall safety was similar to aflibercept, but brolucizumab produced more favourable anatomical outcomes. FDA approval was granted in October 2019 for the treatment of wet age-related macular degeneration (AMD).
Mechanism Of Action and Pharmacodynamic Effects
Intraocular administration of anti-VEGF agents inhibits the aberrant vascularisation in AMD which results from overexpression of VEGF, thereby controlling or slowing disease progression.